Supplementary Files
How to Cite
Abstract
Objective: The occurrence of venous thromboembolism outside the pulmonary arteries or lower extremity conventional deep vein is referred to as deep vein thrombosis (DVT). The optimal anticoagulation treatment for deep vein thrombosis remained debatable. Therefore, the purpose of the current study was to compare Rivaroxaban versus Warfarin in treating deep vein thromboembolism at the Tertiary Care Hospital, Islamabad.
Methods: A randomised controlled trial investigated 170 deep vein thrombosis (DVT) patients in the Department of Medicine, Pakistan Institute of Medical Sciences, Islamabad, from July 2023 to January 2024. Patients were categorised into two groups: Group R (Rivaroxaban) (N=85) and Group W (Warfarin) (N=85). Demographic data, such as age, gender, comorbidities, clinical outcomes, and efficacy recorded for both groups. Major bleeding included any fatal bleeding, bleeding in critical organs, or bleeding causing a haemoglobin drop ≥2 g/dL or requiring ≥2 units of blood transfusion. Minor bleeding is defined as overt bleeding, including events like mild epistaxis or bruising not requiring medical intervention. SPSS version 16 was used for statistical analysis.
Results: The overall mean age of group R and W was 47.78±17.91 years and 46.45±18.01 years, respectively. Out of 170 patients, there were 83 (48.8%) males and 87 (51.2%) females. Gender based distribution of patients in both groups was as follows: Group R, N=85 (Male 42 (49.4%) and female 43 (50.6%) and Group W (Male 41 (48.2%) and female 44 (51.8%). Rivaroxaban (Group-R) showed higher efficacy, 72 (84.7%), than Warfarin (Group-W), 62 (72.9%).
Conclusion: The present study observed that treatment with Rivaroxaban is preferred over Warfarin due to reduced risk of DVT, major bleeding, and minor bleeding.
References
Costa OS, Thompson S, Ashton V, Palladino M, Bunz TJ, Coleman CI. Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis. Thromb J. 2020 8;18:6. https://doi.org/10.1186/s12959-020-00219-w.
Khodashahi M, Rezaieyazdi Z, Sahebari M. Comparison of the Therapeutic Effects of Rivaroxaban Versus Warfarin in Antiphospholipid Syndrome: A Systematic Review. Arch Rheumatol. 2019 12;35(1):107-116. https://doi.org/10.5606/ArchRheumatol 2020.7375.
Coons JC, Albert L, Bejjani A, Iasella CJ. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. Pharmacotherapy. 2020;40(3):204-210. https://doi.org/10.1002/phar.2369.
Berger JS, Laliberté F, Kharat A, Lejeune D, Moore KT, Jung Y et al. Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. Curr Med Res Opin. 2021 ;37(6):881-890. https://doi.org/10.1080/03007995.2021.1901223.
O'Neill ET, Huang AW, Wilson-Barthes M, Manji I, Kigen G, Busakhala N et al. A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya. Clin Drug Investig. 2025 28. https://doi.org/10.1007/s40261-025-01454-7.
Esmaeili S, Abolmaali M, Aarabi S, Motamed MR, Chaibakhsh S, Joghataei MT et al. Rivaroxaban for the treatment of cerebral venous thrombosis. BMC Neurol. 2021 15;21(1):73. https://doi.org/10.1186/s12883-021-02091-1.
Weaver P, Ng TH, Breeden T, Edwin SB, Haan B; ASCEND-HIGHER Research Initiative; Giuliano C. Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin. Ann Pharmacother. 2022 ;56(12):1315-1324. https://doi.org/10.1177/10600280221089008.
Huang Y, Duan L, He W, Hong C, Guo Y, Wang X et al. Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study. Anal Cell Pathol (Amst). 2020 26;2020:6813492. https://doi.org/10.1155/2020/6813492.
Elshafei MN, Mohamed MFH, El-Bardissy A, Ahmed MB, Abdallah I, Elewa H et al. Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. J Thromb Thrombolysis. 2021 ;51(2):388-396. https://doi.org/10.1007/s11239-020-02179-4.
Wik HS, Kahn SR, Eriksson H, Morrison D, Ghanima W, Schulman S et al. Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. J Thromb Haemost. 2021 ;19(10):2495-2503. https://doi.org/10.1111/jth.15449.
Perales IJ, San Agustin K, DeAngelo J, Campbell AM. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Ann Pharmacother. 2020 ;54(4):344-350. https://doi.org/10.1177/1060028019886092.
Kearon C, Carrier M, Gu CS, Schulman S, Bates SM, Kahn SR et al. Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomised Trial. Semin Thromb Hemost. 2020 ;46(8):977-985. https://doi.org/10.1055/s-0040-1718891.
Fu L, Cai W, Li H, Han D, Li L, Wang B. Efficacy and safety of rivaroxaban versus warfarin in the management of unusual site deep vein thrombosis: a retrospective cohort study. Front Pharmacol. 2024 12;15:1419985. https://doi.org/0.3389/fphar.2024.1419985
Kim KA, Choi SY, Kim R. Endovascular Treatment for Lower Extremity Deep Vein Thrombosis: An Overview. Korean J Radiol. 2021;22(6):931-943. https://doi.org/10.3348/kjr.2020.0675.
Li W, Yin Y, Gu C, Fan B, Duan P, Jin Y et al. Modified one-session endovascular treatment for deep venous thrombosis with high risk of pulmonary embolism: Short-term outcomes. Phlebology. 2020 ;35(7):524-532. https://doi.org/10.1177/0268355520904270.
Chopard R, Albertsen IE, Piazza G. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. JAMA. 2020 3;324(17):1765-1776. https://doi.org/10.1001/jama.2020.17272.
Di Nisio M, Valeriani E, Riva N, Schulman S, Beyer-Westendorf J, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost. 2020 ;18(7):1562-1568. https://doi.org/10.1111/jth.14836.
Weimar C, Beyer-Westendorf J, Bohmann FO, Hahn G, Halimeh S, Holzhauer S et al. New recommendations on cerebral venous and dural sinus thrombosis from the German consensus-based (S2k) guideline. Neurol Res Pract. 2024 19;6(1):23. https://doi.org/10.1186/s42466-024-00320-9
Zhang S, Chu W, Wang H, Liang Y, Fan Y, Liu H et al. Evaluation of stability of deep venous thrombosis of the lower extremities using Doppler ultrasound. J Int Med Res. 2020;48(8):300060520942098. https://doi.org/10.1177/0300060520942098.
Wang ZY, Wan YD, Liu XZ, Wang H, Jiang GY, Yang B. A Single-Center, Randomized, Double Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban. Med Sci Monit. 2022 10; 28:e934341. https://doi.org/10.12659/MSM.934341
Kepka S, Cordeanu EM, Zarca K, Frantz AS, Ohlmann P, Andres E et al. A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry. Medicina (Kaunas). 2023 16;59(1):181. https://doi.org/10.3390/medicina59010181.
Singkham N, Phrommintikul A, Pacharasupa P, Norasetthada L, Gunaparn S, Prasertwitayakij N et al. Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation. Pharmaceutics. 2022 21;14(8):1744. https://doi.org/10.3390/pharmaceutics14081744.
Zhang F, Chen X, Wu T, Huang N, Li L, Yuan D et al. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study. Clin Pharmacokinet. 2022 ;61(6):881-893. https://doi.org/10.1007/s40262-022-01108-3.
De Stefano F, Benassi A, Cappelletti AM, Donatelli F, Regazzoli D, Tolaro S et al. On Behalf Of Isnep Investigators. Current Use of Oral Anticoagulation Therapy in Elderly Patients with Atrial Fibrillation: Results from an Italian Multicenter Prospective Study-The ISNEP Study. J Pers Med. 2022 31;12(9):1419. https://doi.org/10.3390/jpm12091419.
Costa OS, Beyer-Westendorf J, Ashton V, Milentijevic D, Moore KT, Bunz TJ et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin. 2020 ;36(7):1081-1088. https://doi.org/ 10.1080/03007995.2020.1762554.
Natale A, Mohanty S, Chen C, Zhao Y, Campbell AK, Bookhart B et al. Clinical and economic outcomes with rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and obstructive sleep apnea: retrospective analysis of US healthcare claims. J Interv Card Electrophysiol. 2024;68(3):613-624. https://doi.org/10.1007/s10840-024-01940-6.
Ranjan R, Ken-Dror G, Sharma P. Direct oral anticoagulants compared to warfarin in long-term management of cerebral venous thrombosis: A comprehensive meta-analysis. Health Sci Rep. 2024 4;7(2):e1869. https://doi.org/10.1002/hsr2.1869
Dobry P, Edwin SB, Haymart B, Barnes GD, Kaatz S, Ali MA et al. Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients. J Thromb Haemost. 2024;22(12):3500-3509. https://doi.org/10.1016/j.jtha.2024.08.009.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2025 Mahnoor Yousaf, Aneza Jalil, Maria Zafar, Zunaira Sajjad, Maham Nasir